conference of patients Ben, busy thank We final the I progress good our for our to appreciate be with want you. continued in We already. to closely, quarter need and innovative your and call and afternoon, share results case incredibly you I'll our third with rest is election Esperion. mission And week, the historic you, Thank will cholesterol. you high go we encourage an nudge, everyone you in and uncontrolled if medicines bring one and watching everyone. to to vote, along know oral it new Today, you joining interest haven't on
to the Esperion ever. environment a focus are significantly a commitment backdrop to health patients. while visits than companies, care, past health which need motivate believe level, of limitations everyone. care Our seeing lowering patients cardiovascular reasons. just with for is long-term cardiovascular to are at high refocus well a myriad about navigate all neglecting report, singular And improve for in cholesterol, highlights reeducate and the company increasingly opportunity This sedentary and for We're to commercialized an medicines. cholesterol, on are telemedicine, and primary physicians go-to we mind, more very relevant. lipid as their of fewer is risk long-term for approaches of increasing our patients dynamic only management commercial launches bad this on cholesterol. has as longer millions seeing With in need energize through like public no a positioned after often are of bad Report continues to The we providers factors increased we as we health ever-widening us, and assessing reliance
that the accessible with providers HCPs, patients, once-daily interested have and A bad need help survey, to our have waking audience providers we an to interactions cholesterol, when launch We non-statin carries building, this big changing company do health to to And care with would number company, educating they appreciates on that a on conducted easy patients cholesterol, around cholesterol. physicians up And and the course. a our see they bigger whatever can both morning The if cardiovascular care commercial new and regarding recognizes was our we a killer health now. the but the confirmed Cardiovascular we find for gives our world. rep for increasing. it disease scary as we pills a They focus long-term care companies key foundation recently prefer is of us with specialists tremendous that build an cholesterol. our we to types company, about This a strong much medicine we cholesterol. remains primary asked, have this and sample, bag. any near bad in It's reality is innovation entire optimism bad by medicines focus one opportunity prefer, and with is element to contribute every truly right a when focused that company. LDL disease plans the a with have tragic on battling pharma and their cardiologists in our disease or a area only in rather and a overwhelmingly specialist the small
oral, pandemic been especially cardiovascular Despite U.S. In fact, XX% innovation XXXX, CDC XXXX. cholesterol in increase they the non-statin addressing by in serious disease lack has need expected medicines. from there to said, of even the this, a lowering, deaths before convenient the for
the neglected We're also patient new unmet a medicines cholesterol-lowering company financial potential goal conform embarked focus needs, area cholesterol disrupting bad to road by at make on with that really market each traditional of on alone LDL like-minded well-worn impact. to the the building our will medicine and adversity times, that major a partners a a So is to societal this tremendous times. non-statin overcomes non-statin our company years at but not XX has and oral companies over knows that fulfill company comes confidently ago a deliver other path. journey takes to medicines, that value, We
to you and I'd Right success of So you with of environment, look ask long-term that environment. an few the mind, countless in the what success are examples long-term insights of launch companies keep in this launches short-term all medicines new not In off? historical I'd ask the metrics, how the like in into home. what this success to customer-facing consider with momentum. we bets As short-term you call launching consider a our have little in one very few, our power industry luxury And when and provide truly do and to do at teams we'll simply we now, looks like. later measure
While on the facing that. in some temporary into getting are hyper-focused obstacles all our we of who need hands we are short-term, them accomplishing the medicines in
story our a broader stakeholders. company. our few However, team's points as progress that additional influence to proof there's a progress key like to on ability of demonstrates a highlight And I'd
for us. from opens to marked our closely unprecedented first, with of expands a European is So the new and stream of Europe expands, for medicines an and practices fact Daiichi very launching in partner will environment. the that that today launch number We've prepare incredible this share benefit our in Sankyo our patients This milestone revenue significantly working best been medicines.
thing We in region. now prelaunch which process virtual the U.K. in year, by the in their there. and available rest are highly one their in Our participated optimistic for early European is meetings, XXXX-person attended launch is well-prepared of were The reimbursement. launch more certain; a launch EU the planned followed extremely Germany, biggest need about our the is access than with DSE to and cardiovascular the and for Europe in team for country-by-country country by staggered line for next the medicines the medicines
the news progress now The to the bempedoic Clinical share making American team Endocrinologists which their or I'd guidelines published our in more updated AACE acid. Next, U.S. lipid some of include is like Association shows the recently that
I'm like you of society any validation the This to we hearing meeting providers or report new provides are to enduring guideline coalition many even which the are include medicines medicine. step for exceeding incorporation their pleased our bempedoic a important know new building. care and that source first of acid, in medical major professional across a As of key board, guidelines is from the medicines lipid in health ours from that is an also expectations.
after and reputation are is patient get and do? to is Third, as years launch with from I'm how patient core but something access, with as of values. pharma many value partnering access groups incredibly how backing proud This say like degradation. we All big this, Esperion we value centric of establish into initial to organization companies start a
start. the are around literally rallying from it We
has is stop I LDL everyone as management we that means purpose Our said everyone. achieved their earlier for levels. lipid don't recommended And until
Just partnerships a our both of work HealthyWomen and couple of the FH are Foundation. group patient examples our with
to are a published, is Heart want And levels We week patients. need U.S. article LDL And Study us these powerful CVOT sound reach content finally, risk underscored echo taking to for million medicines And which additional patients that tolerability highlight together. joint are are the years, surround distinct American to the statin-intolerant. nearly patient cholesterol, statins of who for generating say groups reduction paper. fight in demonstrating XX for issues. approach Outcomes, This patients due the the to reaching heard the design Journal bad CLEAR not to importance last high you cardiovascular considered cholesterol non-statin patients I with
for despite need of or CLEAR options. in objective for will focus statins is believe the events bempedoic ultimate patient In Outcomes unable before study reduce we potential physicians added fact have non-statin to population. the outcome never been in underserved the clear unwilling confidence and take the patients patients treatment risk whose of cardiovascular provide their And this study cardiovascular acid's a to
have are and understand need. ahead. the record environment, continues We're a to environment adapting we're around team, in which in the we however, to for our laid the singular which of deny we proven facing has continue grow. our urgency, a to on we building of this and headwinds momentum aware critical We purpose. create can and can't confident but long-term the company foundation are Our to the stakeholders that listening executing path patient we're keenly We
commercial to efforts. color our So more with Mark? that Mark share over turn on I'll to call the
